DARPA DEFUSE Proposal (2018)
artifactMoney & Finance · Biotech & Transhumanism · Defense & Military-Industrial
A rejected 2018 proposal described building exactly the kind of virus that COVID-19 turned out to be.
Who they are
The DARPA DEFUSE proposal from 2018, authored by Peter Daszak of EcoHealth Alliance with Ralph Baric (UNC) and Shi Zhengli (Wuhan Institute of Virology).
What they do
It sought $14.2 million to engineer bat coronaviruses with human-infecting features.
How it works
The proposal explicitly aimed to insert human-specific cleavage sites (furin cleavage sites) into novel bat coronaviruses, test their ability to bind human cells, and suppress bat immune responses. DARPA rejected it over safety and ethics concerns, but the described blueprint matched the unique genomic features of SARS-CoV-2, and this was concealed from the public in the pandemic's early years despite being known across 15 federal agencies.
Why it matters
The engine ties it to a wider pattern where defense-funded biotech (like a 2013 DARPA grant that seeded Moderna's mRNA technology, later worth billions via Operation Warp Speed) was positioned years before COVID, and connects it to the 2019 Event 201 pandemic simulation, suggesting multiple actors were pre-aligned before the crisis hit.
The engine's record — word for word
Authored by Peter Daszak (EcoHealth Alliance) in partnership with Ralph Baric (UNC) + Shi Zhengli (Wuhan Institute of Virology). Sought $14.2M federal funding under DARPA PREEMPT program. **Explicit content:** insert human-specific proteolytic cleavage sites — specifically furin cleavage sites — into novel bat coronaviruses. Identify viral strains exploiting DC-SIGN pathway. Introduce key RBD residues to test ACE2 affinity in humanized mice. Suppress bat interferon responses. **DARPA rejected** citing safety, Dual Use Research of Concern (DURC), failure to address Ethical/Legal/Social Issues. **The blueprint matched the exact unique genomic characteristics of SARS-CoV-2.** Despite knowledge across 15 federal agencies (including NIH Rocky Mountain Lab listed as partner), concealed from public during critical early years of pandemic. [2026-05-06 COVID Wealth Transfer Audit extension] DARPA→Moderna $25M 2013 grant funded foundational mRNA technology subsequently commercialized via Operation Warp Speed (`operation_warp_speed_contractor_ledger`) yielding $1.5B BARDA contract + record IPO valuation. Pattern: DoD-seeded biotechnology pre-positioned 7 years before COVID-19 commercialization trigger. Cross-reference Event 201 (October 2019 — funded by Open Philanthropy Project + co-hosted by WEF + Gates Foundation; explicitly modeled pandemic-financial-crisis injects mirroring BlackRock's August 2019 Going Direct paper, demonstrating multi-node pre-alignment on impending liquidity interventions per audit Finding 49) — DARPA-DEFUSE 2018 is upstream of both the biological-substrate firing and the financial-architecture default-programming. **Report #84 (May 7 2026 MV Hondius audit - adversarial null cross-reference):** Andes virus has no DEFUSE-equivalent program in the public record. The MV Hondius cluster traces to a routine pre-boarding rodent exposure near Ushuaia, not to any high-containment laboratory program. The lab-leak architecture the engine tracks does NOT extend to this event.
Follow the trail
Walk this on the live map →